Tag - Siamab Therapeutics

Siamab Therapeutics Presents New Data at AACR’s Ovarian Cancer Conference Demonstrating its Anti-STn Antibody Therapeutics Inhibit Tumor Growth in Ovarian Cancer Models

Ziad2022-11-25T14:05:30-05:00Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced the presentation of new preclinical data for its novel anti-Sialyl-Tn (STn) antibodies and antibody drug conjugates (ADCs) that show inhibition of tumor progression in in vivo and in vitro patient derived xenograft (PDX) ovarian cancer models with complete regression in some treatment arms. Read more >>

Siamab Therapeutics Presented New Data for its Anti-STn Antibody Therapeutics Showing Myeloid-Derived Suppressor Cells as a Promising Cancer Immunotherapy Target at Cambridge Healthtech Institute’s Targeting Tumor Myeloid Cells Conference

Ziad2022-11-25T14:05:30-05:00Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced it presented new preclinical data for its novel anti-Sialyl-Tn (STn) antibodies and antibody drug conjugates (ADCs) targeting myeloid-derived suppressor cells (MDSCs) at Cambridge Healthtech Institute’s Inaugural Targeting Tumor Myeloid Cells Conference, held September 27-28, 2017 in Boston. Read more >>

Siamab Therapeutics to Present at the 2017 BIO International Convention

Ziad2022-11-25T14:05:42-05:00Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies targeting tumor-associated carbohydrate antigens (TACAs), today announced that Jeff Behrens, president and chief executive officer, will present at the 2017 BIO International Convention. Read more >>

Siamab Therapeutics Presents New Preclinical Data for Its Novel Anti-STn Antibodies, Antibody-Drug Conjugates, and Anti-STn Bispecific Antibodies at the AACR Annual Meeting 2017

Ziad2022-11-25T14:05:53-05:00Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced the presentation of two posters featuring new preclinical data for its novel anti-Sialyl-Tn (STn) antibodies, antibody-drug conjugates (ADCs), and anti-STn, anti-CD3 bispecific antibodies at the American Association for Cancer Research (AACR) Annual Meeting 2017, being held April 1-5, 2017 in Washington, D.C. Read more >>

Siamab Therapeutics Announces Publication of New Preclinical Data

Ziad2022-11-25T14:05:54-05:00Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced the publication of new preclinical data describing its novel ST1 antibodies targeting, with high affinity and specificity, the Sialyl-Thomasen-nouveau antigen (STn), a tumor-associated carbohydrate antigen (TACA). Read more >>

Siamab Therapeutics Presents Promising Preclinical Data at 2016 AACR Ovarian Cancer Research Symposium

Ziad2022-11-25T14:06:07-05:00Siamab Therapeutics, Inc., a biotechnology company developing novel cancer immunotherapies, today announced new pre-clinical data that showed its novel ST1 antibody drug conjugates (ADCs) target chemoresistant ovarian cancer cells and demonstrate strong efficacy in ovarian cancer models. These data were presented at the American Association for Cancer Research (AACR)’s 11th Biennial Ovarian Cancer Research Symposium 2016 in Seattle, Wash., on Monday, Sept. 12, 2016. Read more >>